Monalisa Mild Lidocaine (1×1ml)

Avoid alcohol for 24h before and 48h after the procedure. Alcohol consumption leads to vasodilation, which can exacerbate post-injection edema and increase the visibility of hematomas at the entry points, complicating the healing process.

The formulation contains 24 mg/ml of monophasic cross-linked Sodium Hyaluronate and 0.3% Lidocaine hydrochloride. This high concentration ensures durability, typically maintaining results for 6 to 12 months.

Dosage is individualized based on the patient's anatomy and the severity of the skin depression. Typically, 1.0 ml is sufficient for a standard lip enhancement or the correction of moderate folds. Practitioners should evaluate if 0.5 ml of filler is sufficient for minor asymmetry corrections before utilizing the full syringe. For robust volume restoration in the mid-face, clinicians may compare its performance to Revolax Deep.

Common reactions include temporary erythema, swelling, and localized purple bruising at the injection sites. These effects are generally mild and resolve within 3 to 7 days. To ensure patient safety, injectors must have Liporase (Hyaluronidase) available in the clinic to manage any unexpected vascular or aesthetic complications immediately.

The gel acts as a mechanical support, physically displacing the mid-dermis to smooth wrinkles while the cross-linked HA matrix binds water molecules to maintain hydration. This dual action provides long-lasting volume that moves naturally with facial expressions. For patients with thin skin, combining this filler with a redensifying agent like Jalupro HMW can enhance the final structural outcome.

This treatment is strictly contraindicated. No clinical safety data exists for cross-linked HA fillers during pregnancy or breastfeeding. Practitioners must monitor for signs of vascular occlusion in all patients and defer elective procedures for pregnant individuals to prioritize maternal and fetal health.